aTYR PHARMA (ATYR) Operating Leases (2019 - 2026)

aTYR PHARMA (ATYR) has reported Operating Leases for 8 consecutive years, with $9.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 8.8% year-over-year to $9.8 million; the trailing twelve-month figure through Jun 2026 stood at $9.8 million (down 8.8% YoY), and the FY2025 full-year result was $10.3 million, down 7.5% from the prior year.
• Operating Leases declined to $9.8 million in Q2 2026 per ATYR's latest filing, from $10.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $12.8 million in Q2 2023 and bottomed at $133000.0 in Q1 2022.
• Historically, Operating Leases has averaged $10.3 million across 5 years, with a median of $11.0 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Operating Leases plunged 88.38% in 2022, then jumped 8859.4% in 2023.
• Over 5 years, Operating Leases stood at $9.6 million in 2022, then climbed by 28.09% to $12.3 million in 2023, then declined by 9.68% to $11.1 million in 2024, then dropped by 7.5% to $10.3 million in 2025, then slipped by 4.94% to $9.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $9.8 million, $10.1 million, and $10.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.